BREAKING
Encompass Health Corporation reports Q4 2025 results, issues 2026 guidance 19 hours ago Graham Corporation Expands Capabilities Across Defense, Energy, and Space Markets 19 hours ago Graham Corporation Sees Robust Q3 on Defense Momentum and FlackTek Integration 20 hours ago Biogen’s Q4 FY25 adj. earnings decline, but beat estimates; revenue down 7% 21 hours ago Infographic: How Philip Morris (PM) performed in Q4 2025 financial results 21 hours ago Abbott reports positive results from study on its atrial fibrillation therapies 22 hours ago Atmus Welcomes Heath Sharp to Board of Directors 24 hours ago Cboe Global Markets Q4 2025 adj. earnings jump on record high revenues 24 hours ago Zurn Elkay beats fourth quarter estimates, forecasts growth for 2026 3 days ago Yum China Reports Fourth Quarter and Full Year 2025 Financial Results 3 days ago Encompass Health Corporation reports Q4 2025 results, issues 2026 guidance 19 hours ago Graham Corporation Expands Capabilities Across Defense, Energy, and Space Markets 19 hours ago Graham Corporation Sees Robust Q3 on Defense Momentum and FlackTek Integration 20 hours ago Biogen’s Q4 FY25 adj. earnings decline, but beat estimates; revenue down 7% 21 hours ago Infographic: How Philip Morris (PM) performed in Q4 2025 financial results 21 hours ago Abbott reports positive results from study on its atrial fibrillation therapies 22 hours ago Atmus Welcomes Heath Sharp to Board of Directors 24 hours ago Cboe Global Markets Q4 2025 adj. earnings jump on record high revenues 24 hours ago Zurn Elkay beats fourth quarter estimates, forecasts growth for 2026 3 days ago Yum China Reports Fourth Quarter and Full Year 2025 Financial Results 3 days ago
ADVERTISEMENT
Market News

Weibo’s Q2 results beat estimates

Weibo Corporation (NASDAQ: WB) surpassed analysts’ expectations for revenue and earnings in the second quarter of 2019, sending shares climbing 5.9% in premarket hours on…

Market News

AbbVie wins FDA approval for Rinvoq, stock gains

Shares of biopharmaceutical firm AbbVie (NYSE: ABBV) jumped 2.1% after the company received approval from the US Food and Drug Administration for its rheumatoid arthritis…